BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...